+

WO1982004395A1 - A process in purification and concentration of the factor viii complex - Google Patents

A process in purification and concentration of the factor viii complex Download PDF

Info

Publication number
WO1982004395A1
WO1982004395A1 PCT/SE1981/000183 SE8100183W WO8204395A1 WO 1982004395 A1 WO1982004395 A1 WO 1982004395A1 SE 8100183 W SE8100183 W SE 8100183W WO 8204395 A1 WO8204395 A1 WO 8204395A1
Authority
WO
WIPO (PCT)
Prior art keywords
factor viii
solution
glycine
concentration
complex
Prior art date
Application number
PCT/SE1981/000183
Other languages
French (fr)
Inventor
Erik Gustaf Birger Blombaeck
Lars Gunnar Thorell
Original Assignee
Erik Gustaf Birger Blombaeck
Lars Gunnar Thorell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erik Gustaf Birger Blombaeck, Lars Gunnar Thorell filed Critical Erik Gustaf Birger Blombaeck
Priority to PCT/SE1981/000183 priority Critical patent/WO1982004395A1/en
Priority to EP19810901787 priority patent/EP0081482A1/en
Publication of WO1982004395A1 publication Critical patent/WO1982004395A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to a process in purification and/or concentration of the factor VIII complex. It is started from a preparation prepared in a manner known per se, in which the factor VIII complex is enriched. The preparation is mostly in the form of a precipitate.
  • the factor VIII complex is lacking or its activity is reduced in hemophilia of type A and in v. Willebrand's disease. The symptoms in these diseases are often serious bleedings in joints and muscles and from mucous membranes.
  • the factor VIII complex takes part in the biochemical reactions promoting the coagulation of blood.
  • an insoluble polymer, fibrin is formed from a soluble protein, fibrinogen.
  • the reason for the polymerization or formation of fibrin is an enzymatic change of the fibrinogen molecule, which is caused by the enzyme trombin (factor Ila).
  • This enzyme is formed from protrombin (factor II) under the influence of an enzyme, called factor Xa.
  • Said enzyme is also present as a zymogen in the blood before the coagulation.
  • factor X The zymogen form is called factor X.
  • factor Xa The conversion of factor X to factor Xa also takes place enzymatically by means of an enzyme called factor IXa.
  • factor VIII complex takes part in this reaction (as a co-factor) together with calcium and phospholipide.
  • the most important reactions in the coagulation (clotting) of blood are illustrate Totally a great number of various factors take part here.
  • the factor VIII complex consists of at least two components, one of which is called the factor VIII : C, in which C means that this component is responsible for the coagulation activity of the complex in the reaction chain shown.
  • This component is considered to contain the antigen proved by means of antibodies, which are developed in certain persons suffering from hemophilia and which prevent the coagulation activity of factor VII I : C .
  • the antigen is called F VIII : CAG.
  • the other component has been called factor VIII-RAG or F VHI-related antigen. This antigen is different from the antigen F VIII : CAG.
  • the factor VIII : C and the (antigen) factor VIII : CAG are lacking in hemophilia of type A in a serious form. In this disease there is a normal content of factor VIII: RAG. In v. Willebrand's disease, there Is a lack of factor
  • factor VIII RAG in the blood and a corresponding lack of factor VIII : C.
  • the lack of factor VIII: RAG is almost total and the content of factor VIII : C is about 5 % of the normal content.
  • the activity of the so-called factor VIII : RCF is highly reduced. This activity is an expression of a component in plasma which causes agglutination of trombocytes in the presence of the antibiotic "Ristocetin”. It is now considered that the activity of the factor VIII : RCF is an expression of the component or components in plasma which has (have) the factor Vlll-related antigen (factor VIII : RAG).
  • Willebrand's disease has been found to be correlated to the prolonged capillary bleeding time existing in this disease and which is an expression of a defective trombocyte function. This function is normal in hemophilia type A, whereas the coagulation time of the blood is prolonged due to the reduced content of factor VIII : C. In v. Willebrand's disease, the coagulation time is also prolonged as there is also a lack of factor VIII : C in this disease, especially in serious forms thereof. The lack of factor VIII : C in v. Willebrand's disease is considered to be a consequence of the lack of factor VIII : RAG/RCF, which seems to act as carrier molecule for factor VIII : C. In accordance with the existing values, one can illustrate the factor VIII -complex schematically in the following way:
  • a number of processes are known at present for the preparation of plasma concentrates for clinical use, which contain the factor VIII complex or parts thereof.
  • the complex can be precipitated from Cohn's fraction I with alcohol. Additional concentration of the complex can be carried out by extraction of inert protein whith about 1 M glycine solution in cold. Fractionation of plasma with ether or tannic acid has also been used for the preparation of factor VIII concentrates. Concentrates prepared by precipitation in cold of the factor VIII complex have been widely used due to the simplicity of the method. In certain cases, polyethylene glycol has been used for precipitation of the factor VIII complex. Variants of the glycine method, in which either other amino acids than glycine have been used or glycine has been used for precipitation of the factor VIII complex are also known.
  • Concentrates prepared according to the glycine method contain all factors in the factor VIII complex, but the specific activity is low, and therefore great volumes of solution must be injected in the treatment of hemophilia. Preparations with a high specific activity have often been found to lack the factor correcting the prolonged bleeding time in v. Willebrand's disease.
  • Hemophilia A as well as v. Willebrand's disease can be treated with such a concentrate.
  • a specific activity which is 200-300 times greater than that In plasma also permits preparations containing the necessary therapeutic dose in a small volume (5-10 ml) . This makes the treatment easier as the dose can be administered in an injection syringe. This also makes it possible to carry out the treatment for example at home by the sick person himself as is usual in the treatment of diabetes with insulin.
  • the process according to the invention is charactericed in that the resulting preparation of factor VIII complex is dissolved in a glycine solution of at least 1.5 M at a temperature of at least +15°C and a pH of 6.3-7.8, preferably pH 6.8, and that supernatant liquid is recovered as a product or for further working-up.
  • the resulting product (factor VIII complex) contains the antihemophilic factor (factor VIII : C/CAG) and the component (factor VIII-RAG/RCF) which is lacking in v. Willebrand's disease.
  • the starting preparation obtained in a way known per se can be prepared by cryoprecipitation or fraction ation of plasma with alcohol.
  • impurities are then precipitated in a glycine solution at and about room temperature and at a neutral pH.
  • glycine solutions have been used at a low temperature for dissolutiqn of impurities from a precipitated factor VIII complex.
  • Glycine at a concentration of about 2 M has also been used for precipitation of the factor VIII complex from a protein solution at a low temperature.
  • the preparation of factor VIII complex is now treated at a temperature of at least 15°C, preferably at a temperature of 15-37o C, such as 20-35oC and most preferably at about 30 °C.
  • the temperature should not normally exceed 40-45°C.
  • the factor VIII complex remains in solution, while contaminating protein is precipitated.
  • the pH is approximately neutral.
  • the ionic strength of the solution should be between 0.1 and 0.5, calculated as buffer salts.
  • the glycine concentration at the precipitation of impurities can vary between 1.5 M and a saturated solution and is preferably 1.6-2.3 M, such as 1.8-2.2 M, and most preferably about 2.0 M.
  • the supernatant liquid can be worked up in a manner known per se by precipitating the factor VIII complex with organic solvent or polymerisolutions.
  • this factor VIII complex also can be precipitated by the addition of salt.
  • salt is added to the supernatant liquid to a concentration of at least 1.5 M maintaining the glycine concentration of at least 1.5 M to precipitate the factor VIII complex containing product which Is recovered.
  • the salt used should be non-toxic and should be able to provide the necessary concentration of at least 1.5 M, e.g. 1.8 M, preferably about 2.0 M or more, e.g. 2.2 M. It is possible to use a saturated salt solu tion.
  • the glycine concentration can be the same as in the dissolving step.
  • the temperature can be as low as the freezing point of the supernatant liquid up to as high temperatures as e.g. 50°C or 60 °C. Temperatures below
  • salts that can be used are NaCl, KCl, CaCl 2 , MgCl 2 , NH 4 Cl, (NH 4 ) 2 SO 4 , Na,SO 4 , K 2 SO 4 , Na 3 PO 4 , Na 2 HPO 4 , NaH 2 PO 4 and citrates of sodium, potassium and ammonium; thus alkaline metal salts, such as sodium and potassium salts and ammonium salts, are preferred.
  • Fig. 1 shows protein and activity in the supernatant liquid and the specific activity as a function of the molarity of the glycine solution.
  • Fig. 2 shows the activity in supernatant liquid and in precipitate and protein in the supernatant liquid as a function of the temperature.
  • Figs. 3 and 4 the same quantities are shown as a function of pH and ionic strength, respectively.
  • Fig. 5 shows the activity in vivo of the factor VIII concentrate in a patient suffering from severe v. Willebrand's disease, and also the inverted value of the bleeding time;
  • Fig. 6 is a diagram Illustrating the yield of factor VIII in the supernatant liquid and the precipitate versus the salt concentration.
  • Example 1 Blood is collected in citrate-phosphate-dex trose-adenine solution in an amount of 50 ml of citrate solution per 430 ml of blood. Blood cells are removed by centrifuging and plasma is sucked off. The plasma is fractionated with alcohol according to Cohn's fractionation method. Fraction I is washed in cold with glycine solution. The remaining precipitate, called fraction 1-0, contains factor VIII complex and is dissolved in sodium citrate solution (pH 6.8) of 0.055 M to a protein concentration of about 2 %. 8 parts of a buffer with a pH of 6.8 and containing varying amounts of glycine, 0.125 M NaCl and 0.025 M imidazole are added to 4 parts of this solution at room temperature.
  • Example 2 Blood and plasma are prepared in the way described in example 1.
  • a counterpart of fraction I-0 is prepared by freezing of the factor VIII complex by adding polyethylene glycol 4000 in an amount of 1 % to the plasma. The mixture is frozen at -70°C. At a slow thawing to +4°C a precipitate called cryoprecipitate remains when all ice has melted. This precipitate contains between 60 and 90 % of the factor VIII complex of the plasma. The precipitate is dissolved in 0.055 M sodium citrate solution (pH 6.8) to a protein content of about 3 % .
  • the separation of the factor VIII complex from inert protein is highly dependent on the temperature of the glycine-protein mixture. At temperatures above 15 °C, the main part of the factor VIII complex is found in the supernatant liquid, while at lower temperatures, the main part is in the precipitate.
  • Example 5 The cryoprecipitate (see example 2) is dissolved in a 0.055 M citrate solution (pH 6.8) to a protein content of about 3 %. 8 parts of buffer containing 3 M glycine, 0.125 M NaCl and 0.025 M imidazole, the pH of which has been adjusted to 6.3: 6.8; 7.3 and 7.8, respectively, are added dropwise to 4 parts of this solution. After stirring for 15 min at 30°C, the precipitate formed is removed by centrifugation and dissolved in citrate solution (pH 6.8). The supernatant liquid and the precipitate are analyzed according to example 1.
  • Example 4 10 parts of glycine-imidazole solution with a varying content of co-men salt were added dropwise to 5 parts of the cryoprecipitate (see examples 2 and 3).
  • the composition of the different additional solutions is as follows:
  • Example 5 Fraction I-0 is dissolved in citrate solution (see example 1) to a protein content of about 2 % . 10 parts of 3 M glycine containing 0.125 M NaCl and 0.025 M imidazole, pH 6.8, are added to 5 parts of the resulting solution. After stirring at 20°C the precipitate (F I) is removed by centrifugation. The supernatant liquid (upper liquid I) is cooled to 4°C. Aqueous polyethylene glycol 6000 of 30 % is then added to a final concentration of 10 % . After stirring for 30 min at 4°C, the precipitate (F II) is removed from supernatant liquid (upper liquid II) by centrifuging.
  • Example 6 10 parts of solution containing 3 M glycine, 0.125 M NaCl and 0.025 M imidazole at pH 6.8 are added to 5 parts of solution of the cryoprecipitate (see example 4) at 20°C. After stirring for 10 min the pre cipitate (F I) formed is removed by centrifuging. The supernatant liquid ( Upper liquid I) is cooled to
  • Example 7 Cryoprecipitate (see example 2) is dissolved in 0.055 M citrate solution, pH 6.8, to a concentration of 3 % . 3.3 parts of a solution containing 2.6 M glycine and 0,025 M imidazole, pH 7.3, are added to 1 part of this solution. The temperature of the mixture is simultaneously brought to 7°C. After the addition, the mixture is brought to equilibrium under stirring at 7°C for 15 min. A precipitate (F I) is formed and removed by centrifugation. The supernatant liquid (Upper liquid I) is saved for analysis.
  • the precipitate is dissolved in 0.055 M citrate solution, pH 6.8, at 30°C to about the same volume as the original cryoprecipitate, after which 3.3 volumes of a solution containing 2.6 M glycine, 0.3 M NaCl and 0.025 M imidazole, pH 6.8, are added. Stirring is carried out at 30°C for 20 min.
  • the precipitate (F II) formed is removed by centrifugation.
  • the supernatant liquid (Upper liquid II) is adjusted to pH 7.5 with a weak sodium hydroxide solution after cooling to 4 °C.
  • An aqueous solution of 30 % polyethylene glycol 6000 is then added dropwise to a concentration of 6.5 % .
  • the mixture is stirred at 4°C for 30 min, after which the precipitate formed is remo ⁇ 'ed by centrifuging.
  • the precipitate (F III) is dissolved in 0.055 M sodium citrate solution containing 0.055 M imidazole, pH 7.40.
  • the supernatant liquid (Upper liquid II) is saved for analysis. All fractions are analyzed in the way described in example 1, and the results appear from the following table 3.
  • Example 8 In the previous examples, the analyses of the factor VIII complex have only comprised factor VIII : C. In the following table 4 analyses of a factor VIII complex is shown, which has been isolated substantially in the way described in example 7.
  • the factor VIII : C can be determined according to Nilsson et al: Acta Med. Scan. 159, 35 (1953) or according to Savidge et al : Thromb. Res. 16 , 355 (1979).
  • the factor VIII : CAG can be determined according to Lazarchick and Hoyer, J. Clin. Invest. 62 , 1048 (1978).
  • the complex contains the same concentration of coagulation factor VIII : C as of factor VIII : CAG.
  • the content of factor VIII : RAG is somewhat higher and the content of factor VIII : RCF (lacking in v. Willebrand's disease) is somewhat lower than of factor VIII : C/CAG.
  • a solution consisting of 2.6 M glycine, 0.3 M NaCl and 25 mM tris is thereafter added at a temperature of 20-30°C to a final concentration of 2 M glycine. Stirring is carried out for 20 min. The precipitate formed is separated by centrifugation. The supernatant is cooled to 4°C, after which solid sodium chloride is added to a final concentration of 2 M. Stirring is carried out for 30 min. after which the precipitate formed is separated by centrifugation. This precipitate is dissolved in 0,055 M sodium citrate solution at a pH of 7.30.
  • the inverted value of the bleeding time is also plotted versus the period of time (hours) elapsed after injection to this patient.
  • the Iwy's method [(Nilsson, Magnusson, Borchgrevink, Thr. Diat. Hamorrh, 10, 223
  • Example 10 A supernatant liquid is prepared from a cryoprecipitate as in example 9. This supernatant is cooled to 4°C and divided in three aliquots; thereafter, solid sodium chlorid is added to each aliquot to a final concentration of 1.0, 1.5 and 2.0 M, respectively. Each aliquot is then treated in the following way: stirring is carried out for 30 minutes, after which the precipitation formed is separated by centrifugation.
  • the precipitation is dissolved in 0.055 M sodium citrate solution at a pH of 7.30.
  • the yield of factor VIII is plotted versus the concentration of NaCl in the diagram of fig.6.
  • the line 0 II and the line F II show the yield, based on the cryoprecipitate, of factor vIII in the supernatant liquid and in the precipitation, respectively.
  • Example 11 is repeated with the exception that room temperature is used Instead of 4 °C during the precipitation with sodium chloride.
  • the following table gives the result from this example; thus the volume and the content of the factor VIII : C is given in units as well as percentage in the cryoprecipitate, the supernatant liquid from the solution process with 2 M glycine solution and in the salt precipitate from the precipitation with 2 M sodium chloride.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A process in purification and/or concentration of factor VIII complex, starting from a preparation of factor VIII complex, obtained and concentrated in a known manner, mostly in the form of a precipitate, such as cryoprecipitate or Cohn's fraction I-0. This preparation is dissolved in a glycine solution of at least 1.5 M at a temperature of at least +15<o>C and pH of 6.3-7.8 and a supernatant liquid is recovered as a product or for further working up, particularly precipitation of the factor VIII complex from the supernatant liquid with more than 1.5 M salt solution maintaining the glycine concentration of at least 1.5 M.

Description

A process in purification and concentration of the factor VIII-complex
This invention relates to a process in purification and/or concentration of the factor VIII complex. It is started from a preparation prepared in a manner known per se, in which the factor VIII complex is enriched. The preparation is mostly in the form of a precipitate.
The factor VIII complex is lacking or its activity is reduced in hemophilia of type A and in v. Willebrand's disease. The symptoms in these diseases are often serious bleedings in joints and muscles and from mucous membranes. The factor VIII complex takes part in the biochemical reactions promoting the coagulation of blood. In the coagulation of blood, an insoluble polymer, fibrin, is formed from a soluble protein, fibrinogen. The reason for the polymerization or formation of fibrin is an enzymatic change of the fibrinogen molecule, which is caused by the enzyme trombin (factor Ila). This enzyme is formed from protrombin (factor II) under the influence of an enzyme, called factor Xa. Said enzyme is also present as a zymogen in the blood before the coagulation. The zymogen form is called factor X. The conversion of factor X to factor Xa also takes place enzymatically by means of an enzyme called factor IXa. The factor VIII complex takes part in this reaction (as a co-factor) together with calcium and phospholipide. In the following scheme the most important reactions in the coagulation (clotting) of blood are illustrate Totally a great number of various factors take part here.
Figure imgf000004_0001
The factor VIII complex consists of at least two components, one of which is called the factor VIII : C, in which C means that this component is responsible for the coagulation activity of the complex in the reaction chain shown. This component is considered to contain the antigen proved by means of antibodies, which are developed in certain persons suffering from hemophilia and which prevent the coagulation activity of factor VII I : C . The antigen is called F VIII : CAG. The other component has been called factor VIII-RAG or F VHI-related antigen. This antigen is different from the antigen F VIII : CAG. The factor VIII : C and the (antigen) factor VIII : CAG are lacking in hemophilia of type A in a serious form. In this disease there is a normal content of factor VIII: RAG. In v. Willebrand's disease, there Is a lack of factor
VIII: RAG in the blood and a corresponding lack of factor VIII : C. For persons suffering from a serious form of v. Willebrand's disease the lack of factor VIII: RAG is almost total and the content of factor VIII : C is about 5 % of the normal content. In v. willebrand's disease, the activity of the so-called factor VIII : RCF is highly reduced. This activity is an expression of a component in plasma which causes agglutination of trombocytes in the presence of the antibiotic "Ristocetin". It is now considered that the activity of the factor VIII : RCF is an expression of the component or components in plasma which has (have) the factor Vlll-related antigen (factor VIII : RAG). The lack of factor VIII : RCF in v. Willebrand's disease has been found to be correlated to the prolonged capillary bleeding time existing in this disease and which is an expression of a defective trombocyte function. This function is normal in hemophilia type A, whereas the coagulation time of the blood is prolonged due to the reduced content of factor VIII : C. In v. Willebrand's disease, the coagulation time is also prolonged as there is also a lack of factor VIII : C in this disease, especially in serious forms thereof. The lack of factor VIII : C in v. Willebrand's disease is considered to be a consequence of the lack of factor VIII : RAG/RCF, which seems to act as carrier molecule for factor VIII : C. In accordance with the existing values, one can illustrate the factor VIII -complex schematically in the following way:
F VIII : RAG/RCF = = F VIII : C/CAG
A number of processes are known at present for the preparation of plasma concentrates for clinical use, which contain the factor VIII complex or parts thereof. The complex can be precipitated from Cohn's fraction I with alcohol. Additional concentration of the complex can be carried out by extraction of inert protein whith about 1 M glycine solution in cold. Fractionation of plasma with ether or tannic acid has also been used for the preparation of factor VIII concentrates. Concentrates prepared by precipitation in cold of the factor VIII complex have been widely used due to the simplicity of the method. In certain cases, polyethylene glycol has been used for precipitation of the factor VIII complex. Variants of the glycine method, in which either other amino acids than glycine have been used or glycine has been used for precipitation of the factor VIII complex are also known. Concentrates prepared according to the glycine method contain all factors in the factor VIII complex, but the specific activity is low, and therefore great volumes of solution must be injected in the treatment of hemophilia. Preparations with a high specific activity have often been found to lack the factor correcting the prolonged bleeding time in v. Willebrand's disease.
As to the yield of the coagulation active part (F VII : C), this is low in most preparation processes or between 20 and 30 % at best.
In the treatment of hemophilia, it is of a great importance to use concentrates of the F VIII complex with a high specific acitivity of all the factors included in the complex. Hemophilia A as well as v. Willebrand's disease can be treated with such a concentrate. A specific activity which is 200-300 times greater than that In plasma also permits preparations containing the necessary therapeutic dose in a small volume (5-10 ml) . This makes the treatment easier as the dose can be administered in an injection syringe. This also makes it possible to carry out the treatment for example at home by the sick person himself as is usual in the treatment of diabetes with insulin.
In most countries, the supply of blood is unsatisfactory In respect of the possibilities of preparing sufficient amounts of factor VIII complex for treatment of hemophilia from available blood volumes. This situation might be considerably improved if the percentage yield of the factor VIII complex could be increased in preparation from blood. It has now been found to be possible to prepare a highly satisfactory factor VIII complex having a specific activity that is about 150-250 times greater than that in plasma, while the yield is between 40 and 60 % . The process according to the invention is charactericed in that the resulting preparation of factor VIII complex is dissolved in a glycine solution of at least 1.5 M at a temperature of at least +15°C and a pH of 6.3-7.8, preferably pH 6.8, and that supernatant liquid is recovered as a product or for further working-up. The resulting product (factor VIII complex) contains the antihemophilic factor (factor VIII : C/CAG) and the component (factor VIII-RAG/RCF) which is lacking in v. Willebrand's disease. The starting preparation obtained in a way known per se can be prepared by cryoprecipitation or fraction ation of plasma with alcohol. Through the process of the invention, impurities are then precipitated in a glycine solution at and about room temperature and at a neutral pH. In previously known processes, glycine solutions have been used at a low temperature for dissolutiqn of impurities from a precipitated factor VIII complex. Glycine at a concentration of about 2 M has also been used for precipitation of the factor VIII complex from a protein solution at a low temperature.
According to the invention, the preparation of factor VIII complex is now treated at a temperature of at least 15°C, preferably at a temperature of 15-37º C, such as 20-35ºC and most preferably at about 30 °C. The temperature should not normally exceed 40-45°C.
In doing this, the factor VIII complex remains in solution, while contaminating protein is precipitated. The pH is approximately neutral. The ionic strength of the solution should be between 0.1 and 0.5, calculated as buffer salts. The glycine concentration at the precipitation of impurities can vary between 1.5 M and a saturated solution and is preferably 1.6-2.3 M, such as 1.8-2.2 M, and most preferably about 2.0 M. By this precipitation of protein which is inert in this connect ion, the specific activity in the supernatant liquid is increased by 2-7 times and the yield is between 80 and 100 % .
The supernatant liquid can be worked up in a manner known per se by precipitating the factor VIII complex with organic solvent or polymerisolutions. However, according to a novel technic this factor VIII complex also can be precipitated by the addition of salt. Thus, salt is added to the supernatant liquid to a concentration of at least 1.5 M maintaining the glycine concentration of at least 1.5 M to precipitate the factor VIII complex containing product which Is recovered. The salt used should be non-toxic and should be able to provide the necessary concentration of at least 1.5 M, e.g. 1.8 M, preferably about 2.0 M or more, e.g. 2.2 M. It is possible to use a saturated salt solu tion. The glycine concentration can be the same as in the dissolving step. The temperature can be as low as the freezing point of the supernatant liquid up to as high temperatures as e.g. 50°C or 60 °C. Temperatures below
40°C are preferred, as 0-37°C, e.g. 2-30°C Examples of salts that can be used are NaCl, KCl, CaCl2, MgCl2, NH4Cl, (NH4)2SO4, Na,SO4, K2SO4, Na3PO4, Na2HPO4, NaH2PO4 and citrates of sodium, potassium and ammonium; thus alkaline metal salts, such as sodium and potassium salts and ammonium salts, are preferred.
The invention is described more in detail in the following examples with reference to Its use in the fractionation of blood plasma. In the examples, it is referred to the enclosed drawing, in which Fig. 1 shows protein and activity in the supernatant liquid and the specific activity as a function of the molarity of the glycine solution. Fig. 2 shows the activity in supernatant liquid and in precipitate and protein in the supernatant liquid as a function of the temperature. In Figs. 3 and 4 the same quantities are shown as a function of pH and ionic strength, respectively. Fig. 5 shows the activity in vivo of the factor VIII concentrate in a patient suffering from severe v. Willebrand's disease, and also the inverted value of the bleeding time; Fig. 6 is a diagram Illustrating the yield of factor VIII in the supernatant liquid and the precipitate versus the salt concentration.
Example 1. Blood is collected in citrate-phosphate-dex trose-adenine solution in an amount of 50 ml of citrate solution per 430 ml of blood. Blood cells are removed by centrifuging and plasma is sucked off. The plasma is fractionated with alcohol according to Cohn's fractionation method. Fraction I is washed in cold with glycine solution. The remaining precipitate, called fraction 1-0, contains factor VIII complex and is dissolved in sodium citrate solution (pH 6.8) of 0.055 M to a protein concentration of about 2 %. 8 parts of a buffer with a pH of 6.8 and containing varying amounts of glycine, 0.125 M NaCl and 0.025 M imidazole are added to 4 parts of this solution at room temperature. After stirring for 15 minutes the precipitate formed is removed by centrifugation at ambient temperature. The precipitate is dissolved in citrate solution. The precipitate as well as the supernatant liquid is analyzed in respect of activity of factor VIII : C (normalization of the coagulation time of plasma from persons with hemophilia A after recalcification) or with a commercial reagent (IMCO AB, Stockholm). The total protein is determined by means of Lowry's method. The results of this test appear from Fig. 1. As shown in the figure, considerable amounts of inert protein are precipitated from the solution of fraction I-0 at glycine concentrations of 1.1-2.2 M. When the glycine content in- creases over 2.2, additional precipitation of inert protein takes place, but considerable losses of factor VIII : C can occur from the supernatant liquid. At a glycine content of 1.5-2.0 M, the yield of factor VIII : C in the supernatant liquid is high, while the content of protein therein is much lower than in the original solution. The specific activity of the supernatant liquid is about 5 times higher than in the original solution at a glycine concentration of 2 M.
Example 2. Blood and plasma are prepared in the way described in example 1. A counterpart of fraction I-0 is prepared by freezing of the factor VIII complex by adding polyethylene glycol 4000 in an amount of 1 % to the plasma. The mixture is frozen at -70°C. At a slow thawing to +4°C a precipitate called cryoprecipitate remains when all ice has melted. This precipitate contains between 60 and 90 % of the factor VIII complex of the plasma. The precipitate is dissolved in 0.055 M sodium citrate solution (pH 6.8) to a protein content of about 3 % . 10 parts of a buffer containing 3.0 M glycine, 0.125 M NaCl and 0.025 M imidazole (pH 6.8) are added to 5 parts of this solution at 10º, 20º, 30º and 37ºC. The mixtures are brought to equilibrium at the different temperatures under stirring for 15 min. The precipitate formed is removed by centrifugation. Precipitate and supernatant liquid are analyzed as in example 1.
As is apparent from Fig. 2, the separation of the factor VIII complex from inert protein is highly dependent on the temperature of the glycine-protein mixture. At temperatures above 15 °C, the main part of the factor VIII complex is found in the supernatant liquid, while at lower temperatures, the main part is in the precipitate.
Example 5. The cryoprecipitate (see example 2) is dissolved in a 0.055 M citrate solution (pH 6.8) to a protein content of about 3 %. 8 parts of buffer containing 3 M glycine, 0.125 M NaCl and 0.025 M imidazole, the pH of which has been adjusted to 6.3: 6.8; 7.3 and 7.8, respectively, are added dropwise to 4 parts of this solution. After stirring for 15 min at 30°C, the precipitate formed is removed by centrifugation and dissolved in citrate solution (pH 6.8). The supernatant liquid and the precipitate are analyzed according to example 1.
As is evident from Fig. 3, the differences In activity and yield at different pH are relatively small. An optimal separation of the factor VIII complex en behalf of supernatant liquid is obtained at approximately neutral pH.
Example 4. 10 parts of glycine-imidazole solution with a varying content of co-men salt were added dropwise to 5 parts of the cryoprecipitate (see examples 2 and 3). The composition of the different additional solutions is as follows:
1) 3 M glycine, 0.025 M imidazole, pH 6,8; 2) 3 M glycine, 0.025 M imidazole, 0.3 M NaCl, pH 6.8; 3) 3 M glycine, 0.025 M imidazole, 0.6 M NaCl, pH 6.8.
After achieving equilibrium at 30°C. for 15 min the resulting precipitates are removed by centrifuging. The supernatant l iqu id and the prec ipit ate are analyz ed according to example 1.
The results are shown in Fig. 4. The variation in ionic strength between 0.1 and 0.5 has only a small effect on the distribution of the factor VIII complex in supernatant liquid and precipitate.
Example 5. Fraction I-0 is dissolved in citrate solution (see example 1) to a protein content of about 2 % . 10 parts of 3 M glycine containing 0.125 M NaCl and 0.025 M imidazole, pH 6.8, are added to 5 parts of the resulting solution. After stirring at 20°C the precipitate (F I) is removed by centrifugation. The supernatant liquid (upper liquid I) is cooled to 4°C. Aqueous polyethylene glycol 6000 of 30 % is then added to a final concentration of 10 % . After stirring for 30 min at 4°C, the precipitate (F II) is removed from supernatant liquid (upper liquid II) by centrifuging. All supernatant liquids and precipitates are analyzed in the way described In example 1. The distribution of the protein and the factor VIII complex in the different fractions is apparent from the following table 1. As is apparent from the table, the fraction I-0 is suitable as a starting material for fractionation. The results show, which is most important, that the factcr VIII complex in the supernatant liquid can be concentrated by precipitation with polyethylene glycol after precipitation of inert protein with glycine.
Figure imgf000012_0001
Example 6. 10 parts of solution containing 3 M glycine, 0.125 M NaCl and 0.025 M imidazole at pH 6.8 are added to 5 parts of solution of the cryoprecipitate (see example 4) at 20°C. After stirring for 10 min the pre cipitate (F I) formed is removed by centrifuging. The supernatant liquid ( Upper liquid I) is cooled to
4°C, after which an aqueous solution of 30 % of polyethylene glycol 6000 is added dropwise to a concentration of 6 %. After stirring for 30 min the precipitate (F II) is removed from the supernatant liquid (upper liquid II)by centrifugation. All fractions are analyzed in the way described.
The results of the test appear from table 2. It is apparent from this that cryoprecipitate as well as fraction I-0 is suitable for this type of fractionation. The test also shows that the factor VIII complex, which according to the invention has been obtained in the supernatant liquid, can be concentrated by precipitation with polyethylene glycol.
Figure imgf000014_0001
Example 7. Cryoprecipitate (see example 2) is dissolved in 0.055 M citrate solution, pH 6.8, to a concentration of 3 % . 3.3 parts of a solution containing 2.6 M glycine and 0,025 M imidazole, pH 7.3, are added to 1 part of this solution. The temperature of the mixture is simultaneously brought to 7°C. After the addition, the mixture is brought to equilibrium under stirring at 7°C for 15 min. A precipitate (F I) is formed and removed by centrifugation. The supernatant liquid (Upper liquid I) is saved for analysis. The precipitate is dissolved in 0.055 M citrate solution, pH 6.8, at 30°C to about the same volume as the original cryoprecipitate, after which 3.3 volumes of a solution containing 2.6 M glycine, 0.3 M NaCl and 0.025 M imidazole, pH 6.8, are added. Stirring is carried out at 30°C for 20 min. The precipitate (F II) formed is removed by centrifugation. The supernatant liquid (Upper liquid II) is adjusted to pH 7.5 with a weak sodium hydroxide solution after cooling to 4 °C. An aqueous solution of 30 % polyethylene glycol 6000 is then added dropwise to a concentration of 6.5 % . The mixture is stirred at 4°C for 30 min, after which the precipitate formed is remoλ'ed by centrifuging. The precipitate (F III) is dissolved in 0.055 M sodium citrate solution containing 0.055 M imidazole, pH 7.40. The supernatant liquid (Upper liquid II) is saved for analysis. All fractions are analyzed in the way described in example 1, and the results appear from the following table 3.
Figure imgf000016_0001
Example 8. In the previous examples, the analyses of the factor VIII complex have only comprised factor VIII : C. In the following table 4 analyses of a factor VIII complex is shown, which has been isolated substantially in the way described in example 7.
Figure imgf000017_0001
Remark: The factor VIII : C can be determined according to Nilsson et al: Acta Med. Scan. 159, 35 (1953) or according to Savidge et al : Thromb. Res. 16 , 355 (1979). The factor VIII : CAG can be determined according to Lazarchick and Hoyer, J. Clin. Invest. 62 , 1048 (1978).
It is apparent from the table that the complex, expressed in percent, contains the same concentration of coagulation factor VIII : C as of factor VIII : CAG. The content of factor VIII : RAG is somewhat higher and the content of factor VIII : RCF (lacking in v. Willebrand's disease) is somewhat lower than of factor VIII : C/CAG.
It is evident that products with a high specific activity and a high solubility can be obtained in a good yield at fractionation with glycine according to the invention in combination with other frationating processes. Furthermore, these preparations contain all the activities which in addition to F VIII : C are associated with the factor VIII complex. In comparison with plasma (the specific VIII : C activity of which is about 0.014 U/mg), the specific activity of the product will be 150-250 times greater, the yield from plasma under optimal conditions being 40-60 % Example 9 The cryoprecipitate is prepared as in example 2 and dissolved in 0.555 M sodium citrate solution, pH 7.30, to a protein content of about 3 % . A solution consisting of 2.6 M glycine, 0.3 M NaCl and 25 mM tris is thereafter added at a temperature of 20-30°C to a final concentration of 2 M glycine. Stirring is carried out for 20 min. The precipitate formed is separated by centrifugation. The supernatant is cooled to 4°C, after which solid sodium chloride is added to a final concentration of 2 M. Stirring is carried out for 30 min. after which the precipitate formed is separated by centrifugation. This precipitate is dissolved in 0,055 M sodium citrate solution at a pH of 7.30. The procedure described above gives for F VIII : C a final product in a yield and purification of 30-40 % and 195 times, respectively, calculated from plasma and for F VIII :RCF 60-70% and 430 times, respectively. In a clinical test on a patient suffering from a serious form of v. Willebrand's disease this concentrate has normalized the prolonged bleeding time and increased the level of F VIII :C in plasma to 55% (Fig. 5). This shows that the preparation is suitable in treatment of patients with hemophilic diseases.
The inverted value
Figure imgf000018_0001
of the bleeding time is also plotted versus the period of time (hours) elapsed after injection to this patient. The Iwy's method [(Nilsson, Magnusson, Borchgrevink, Thr. Diat. Hamorrh, 10, 223
(1963)] and the Duke's method [J.A.M.A. 55:1185-1192 (1910)] have been used. Normal Inverted bleeding time is more than 0.2 min-1 and 0.43 min-1 for Iwy's method and Duke's method respectively. Example 10. A supernatant liquid is prepared from a cryoprecipitate as in example 9. This supernatant is cooled to 4°C and divided in three aliquots; thereafter, solid sodium chlorid is added to each aliquot to a final concentration of 1.0, 1.5 and 2.0 M, respectively. Each aliquot is then treated in the following way: stirring is carried out for 30 minutes, after which the precipitation formed is separated by centrifugation. The precipitation is dissolved in 0.055 M sodium citrate solution at a pH of 7.30. The yield of factor VIII is plotted versus the concentration of NaCl in the diagram of fig.6. The line 0 II and the line F II show the yield, based on the cryoprecipitate, of factor vIII in the supernatant liquid and in the precipitation, respectively.
Example 11. Example 9 is repeated with the exception that room temperature is used Instead of 4 °C during the precipitation with sodium chloride. The following table gives the result from this example; thus the volume and the content of the factor VIII : C is given in units as well as percentage in the cryoprecipitate, the supernatant liquid from the solution process with 2 M glycine solution and in the salt precipitate from the precipitation with 2 M sodium chloride.
Figure imgf000019_0001

Claims

1. A process in purification and/or concentration of factor VIII complex, starting from a preparation of factor VIII complex obtained and concentrated in a known manner, most often in the form of a precipitate, c h a r a c t e r i z e d in that the preparation is dissolved in a glycine solution of at least 1.5 M at a temperature of at least +15°C and a pH of 6.5-7.8, and that a supernatant liquid is recovered as the product or for further working up or that optionally salt is added to the supernatant liquid to a concentration of at least 1.5 M maintaining the glycine concentration of at least 1.5 M to precipitate the factor VIII complex containing product which is recovered.
2. The process of claim 1. c h a r a c t e r i z e d in that it is started from a cryoprecipitate or from Cohn's fraction I-0.
3. The process of claim 1 or 2. c h a r a c t e r i z e d in that the Ionic strength of the solution is 0.1-0.5.
4. The process of any of claims 1-3, c h a r a c t e r i z e d in that the temperature is between 20 and 40°C, preferably 25-37°C.
5. The process of any one of claims 1-4, c h a r a ct e r i z e d in that pH Is adjusted to 6.5-7.5, preferably to about 6.8, before the precipitation with glycine solution.
6. The process of any one of claims 1-5, c h a r a ct e r i z e d in that the glycine solution Is a saturated solution, preferably a solution of 1.8-2.2 M, such as about 2.0 M.
7. The process of any one of claims 1-6, wherein the salt is sodium chloride.
8. The process of any one of claims 1-7, wherein the salt precipitation is carried out at a temperature from the freezing point of the supernatant to 60°C.
PCT/SE1981/000183 1981-06-18 1981-06-18 A process in purification and concentration of the factor viii complex WO1982004395A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/SE1981/000183 WO1982004395A1 (en) 1981-06-18 1981-06-18 A process in purification and concentration of the factor viii complex
EP19810901787 EP0081482A1 (en) 1981-06-18 1981-06-18 A process in purification and concentration of the factor viii complex

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE1981/000183 WO1982004395A1 (en) 1981-06-18 1981-06-18 A process in purification and concentration of the factor viii complex
WOSE81/00183810618 1981-06-18

Publications (1)

Publication Number Publication Date
WO1982004395A1 true WO1982004395A1 (en) 1982-12-23

Family

ID=20342875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1981/000183 WO1982004395A1 (en) 1981-06-18 1981-06-18 A process in purification and concentration of the factor viii complex

Country Status (2)

Country Link
EP (1) EP0081482A1 (en)
WO (1) WO1982004395A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0270516A3 (en) * 1986-11-03 1988-06-22 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Process for the preparation of a fraction containing factor viii (ahf)
RU2142290C1 (en) * 1993-05-07 1999-12-10 Фармациа Актиеболаг Aqueous solution of factor viii at decreased oxygen concentration
US6579723B1 (en) 1997-02-27 2003-06-17 Baxter Aktiengesellschaft Method of recovering highly purified vWF or factor VIII/vWF-complex

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3631018A (en) * 1970-05-01 1971-12-28 Baxter Laboratories Inc Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate
US3920625A (en) * 1973-06-19 1975-11-18 Kabi Ab Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
US4081431A (en) * 1974-12-14 1978-03-28 Biotest-Serum-Institut Gmbh Blood fractionation
DE2854381A1 (en) * 1977-12-19 1979-06-21 Geb Dolan Gail Ann Rock PROCESS FOR THE OBTAINMENT OF ANTIHAEMOPHILIC FACTOR VIII FROM BLOOD, BLOOD PLASMA OR BLOOD PLASMA FRACTIONS
DE2848529A1 (en) * 1978-11-09 1980-05-29 Behringwerke Ag METHOD FOR PRODUCING THE REFRIGERABLE GLOBULIN AND MEDICINAL PRODUCTS CONTAINING IT
US4229435A (en) * 1978-01-25 1980-10-21 Blombaeck Birger E G Preparation of blood fraction
DE2916711A1 (en) * 1979-04-25 1980-11-06 Behringwerke Ag Blood coagulation factors and process for their manufacture

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3631018A (en) * 1970-05-01 1971-12-28 Baxter Laboratories Inc Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate
US3920625A (en) * 1973-06-19 1975-11-18 Kabi Ab Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates
US4081431A (en) * 1974-12-14 1978-03-28 Biotest-Serum-Institut Gmbh Blood fractionation
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
DE2854381A1 (en) * 1977-12-19 1979-06-21 Geb Dolan Gail Ann Rock PROCESS FOR THE OBTAINMENT OF ANTIHAEMOPHILIC FACTOR VIII FROM BLOOD, BLOOD PLASMA OR BLOOD PLASMA FRACTIONS
US4229435A (en) * 1978-01-25 1980-10-21 Blombaeck Birger E G Preparation of blood fraction
DE2848529A1 (en) * 1978-11-09 1980-05-29 Behringwerke Ag METHOD FOR PRODUCING THE REFRIGERABLE GLOBULIN AND MEDICINAL PRODUCTS CONTAINING IT
DE2916711A1 (en) * 1979-04-25 1980-11-06 Behringwerke Ag Blood coagulation factors and process for their manufacture

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Arkiv for kemi, Volume 12, no 36, issued 1958 (ALMQVIST & WIKSELL, Stockholm),M BLOMBACK, "Purification of antihemophilic globulin", see pages 387-396, especially pages 392 and 395 ("Summary") *
British Journal of Eaematology, Volume 23, no 1, issued 1972 (Oxford), C SIMONETTI et al, "Studies on the Adsorption of Factor VIII: Application to the Purification of Bovine Factor VIII", see pages 29-36, especially page 30 and page 35 ("Discussion") *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0270516A3 (en) * 1986-11-03 1988-06-22 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Process for the preparation of a fraction containing factor viii (ahf)
US4814435A (en) * 1986-11-03 1989-03-21 Immuno Aktiengesellschaft Fur Chemisch-Medizinisch Produkte Method of producing a factor VIII (AHF) containing fraction
RU2142290C1 (en) * 1993-05-07 1999-12-10 Фармациа Актиеболаг Aqueous solution of factor viii at decreased oxygen concentration
US6579723B1 (en) 1997-02-27 2003-06-17 Baxter Aktiengesellschaft Method of recovering highly purified vWF or factor VIII/vWF-complex

Also Published As

Publication number Publication date
EP0081482A1 (en) 1983-06-22

Similar Documents

Publication Publication Date Title
USRE29698E (en) Stabilization of AHF using heparin
US3631018A (en) Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate
US4203891A (en) Method of collecting anti-hemophilic factor VIII from blood and blood plasma using heparin or sodium heparin
US3931399A (en) Process for isolating a fibrin-stabilizing factor
CA1126652A (en) Antithrombin preparation and process for the production thereof
EP0032655B1 (en) A process in purification and concentration of the factor viii-complex
US4297344A (en) Blood coagulation factors and process for their manufacture
DE69333724T2 (en) HYBRID HUMAN-PIGISH FACTOR VIII
US3682881A (en) Fractionation of plasma using glycine and polyethylene glycol
US4670544A (en) Process for the manufacture of the cold insoluble globulin and pharmaceutical preparation containing it
EP0469985B1 (en) Process for manufacturing von Willebrand factor having a very high purity
JPH06511018A (en) Plasma fractionation purification method
US4087415A (en) Antithrombin III
USH1509H (en) Heparin enhanced process for separating antihemophilic factor (Factor VIII) and fibronectin from cryoprecipitate
EP0148843B1 (en) A concentrate of the antihemophilic factor viii and a process for producing it
EP0077119A2 (en) Collection of antihemophilic factor VIII
JPH0348888B2 (en)
US4081432A (en) Method of separating a Factor IX preparation from plasma using ethylene-maleic anhydride polymers
US3904751A (en) Process for isolating a fibrin stabilizing factor from human placenta
CA1293941C (en) Method for preparing antihemophilic factor (ahf) by cold precipitation and for improving solubility of recovered ahf product
CA1182748A (en) Method for synthesizing procoagulant factor viii activity
US4977246A (en) High recovery process for antihemophilic factor
AU1642992A (en) Preparation of factor ix
JPS63108000A (en) Method for purifying factor 8
WO1982004395A1 (en) A process in purification and concentration of the factor viii complex

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): BR DK FI JP NO SU US

AL Designated countries for regional patents

Designated state(s): AT CH DE FR GB NL SE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载